Document 0562
 DOCN  M9440562
 TI    Regression in basal cell carcinoma: an immunohistochemical analysis.
 DT    9404
 AU    Hunt MJ; Halliday GM; Weedon D; Cooke BE; Barnetson RS; Department of
       Dermatology, Royal Prince Alfred Hospital, Sydney,; Australia.
 SO    Br J Dermatol. 1994 Jan;130(1):1-8. Unique Identifier : AIDSLINE
       MED/94137569
 AB    Spontaneous regression of some cutaneous tumours is well recognized, and
       is thought to result from an immunological response to the tumour.
       Regression has previously been noted in basal cell carcinomas, but no
       studies defining the role of the immune response in the regression of
       this malignancy have been performed. We have examined 45 primary basal
       cell carcinomas (BCCs) (20 nodular, 25 superficial) and identified the
       cellular phenotypes and activation states of the cells infiltrating
       primary regressing and non-regressing BCCs, by immunocytochemistry. We
       have found a significantly increased number of CD3+ and CD4+ T cells
       infiltrating regressing compared with non-regressing tumours, and the
       expression of interleukin-2 receptor (an early activation marker for T
       cells) was also increased. There were no significant differences in
       class II major histocompatibility complex (MHC), CD1, or macrophage
       antigen expression in these groups. These findings suggest that
       activated CD4+ cytokine-secreting cells are important in the regression
       of BCCs.
 DE    Carcinoma, Basal Cell/*IMMUNOLOGY/PATHOLOGY  Comparative Study  CD4-CD8
       Ratio  Female  Human  Immunohistochemistry  Leukocyte Count  Male
       Middle Age  Neoplasm Regression, Spontaneous/*IMMUNOLOGY/PATHOLOGY
       Receptors, Interleukin-2/IMMUNOLOGY  Skin/PATHOLOGY  Skin
       Neoplasms/*IMMUNOLOGY/PATHOLOGY  Support, Non-U.S. Gov't
       T-Lymphocytes/*IMMUNOLOGY/PATHOLOGY  T4 Lymphocytes/PATHOLOGY  JOURNAL
       ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).